Novartis Reports Missed Q1 Estimates, Reaffirms Full-Year 2026 Guidance
Novartis (NVS) reported a Q1 core EPS decline of 15% to $1.99, missing analyst estimates, while net sales fell 1% year-over-year to $13.11 billion. The company reaffirmed its full-year 2026 guidance, projecting low single-digit growth in net sales and a low single-digit decline in core operating income.
Tickers: $NVS
Topics: Earnings Financial Performance Novartis Pharmaceutical Industry